Filed Pursuant to Rule 424(b)(3)
                      Registration Statement No. 333-50024

PROSPECTUS

                                1,131,194 SHARES

[COMPANY LOGO]

                          PROFESSIONAL DETAILING, INC.

                                  Common Stock

                                  ------------

Certain selling stockholders are offering 1,131,194 shares of our common stock.

Our common stock is listed on the Nasdaq National Market system under the symbol
"PDII." On November 28, 2000, the last reported sale price of our common stock
on the Nasdaq National Market system was $132.8125 per share.

Investing in our common stock involves risks. See "Risk Factors" beginning on
page 6.

Neither the Securities and Exchange Commission nor state securities regulators
have approved or disapproved these securities, or determined if the information
contained in this prospectus is accurate or complete. Any representation to the
contrary is a criminal offense.

               The date of this Prospectus is November 28, 2000



                                TABLE OF CONTENTS

                                                                            Page
Where You Can Find More Information.......................................     3
Reports to Security Holders...............................................     3
Incorporation of Certain Documents by Reference...........................     3
Special Note Regarding Forward-Looking Statements.........................     4
The Company...............................................................     5
Risk Factors..............................................................     6
Use of Proceeds...........................................................    15
Selling Stockholders......................................................    15
Plan of Distribution......................................................    16
Legal Matters.............................................................    17
Experts...................................................................    17

      You may rely only on the information contained in this prospectus. We have
not authorized anyone to provide information that is different from that
contained in this prospectus. This prospectus may only be used where it is legal
to sell these securities. The information in this prospectus may not be accurate
after the date appearing on the cover.


                                       2


                       WHERE YOU CAN FIND MORE INFORMATION

      We are required to comply with the informational and reporting
requirements of the Securities Exchange Act of 1934, as amended. In accordance
with that statute, we have filed various reports, proxy statements and other
information with the Securities and Exchange Commission. You may inspect these
reports, proxy statements and other information at the public reference
facilities of the Securities and Exchange Commission at its principal offices at
Judiciary Plaza, Room 1024, 450 Fifth Street, N.W., Washington, D.C. 20549, and
at its regional offices located at 500 West Madison Street, Suite 1400, Chicago,
Illinois 60661-2511, and 7 World Trade Center, Suite 1300, New York, New York
10048. You can get copies of these reports, proxy statements and other
information from these offices upon payment of the required fees. Please call
the Securities and Exchange Commission at (800) SEC-0330 for further information
regarding the operation of its public reference room. These reports, proxy
statements and other information can also be accessed over the Internet at the
web site maintained by the Securities and Exchange Commission at
http://www.sec.gov.

      We have filed a registration statement on Form S-3 with the Securities and
Exchange Commission under the Securities Act regarding the shares of our common
stock covered by this prospectus. This prospectus, which forms a part of that
registration statement, does not contain all of the information included in that
registration statement and its accompanying exhibits. Statements contained in
this prospectus regarding the contents of any document are not necessarily
complete and are qualified in their entirety by that reference. You should refer
to the actual document as filed with the Securities and Exchange Commission.

                           Reports to Security Holders

      We furnish our stockholders with annual reports containing audited
financial statements. In addition, we are required to file reports on Forms 8-K,
10-Q and 10-K with the Securities and Exchange Commission.

                 INCORPORATION OF CERTAIN DOCUMENTS BY REFERENCE

      The following documents filed by us with the Securities and Exchange
Commission are incorporated in this prospectus by reference:

      (1)   Annual Report on Form 10-K for the fiscal year ended December 31,
            1999;
      (2)   Quarterly Report on Form 10-Q for the quarters ended March 31, June
            30 and September 30, 2000;
      (3)   Definitive proxy statement dated May 10, 2000; and
      (4)   Registration Statement on Form 8-A, filed May 13, 1998.

      Each document filed after the date of this prospectus under Section 13(a),
13(c), 14 or 15(d) of the Securities Exchange Act but before this offering
terminates is incorporated in this prospectus by reference and is to be treated
as part of this prospectus as of the date it is filed. Any statement contained
in a document incorporated or deemed to be incorporated in this prospectus by
reference is modified or superseded to the extent that a statement contained in
this prospectus or in any other subsequently filed document that is incorporated
in this prospectus by reference modifies or supersedes that statement.


                                       3


      Upon written or oral request, we will provide, without charge, each person
to whom a copy of this prospectus is delivered, a copy of any document
incorporated by reference in this prospectus (other than exhibits, unless those
exhibits are specifically incorporated by reference in those documents).
Requests should be directed to Professional Detailing, Inc. Professional
Detailing, Inc., 10 Mountainview Road, Upper Saddle River, New Jersey 07458,
Attention: Corporate Secretary.

      NO PERSON HAS BEEN AUTHORIZED TO GIVE ANY INFORMATION OR TO MAKE ANY
REPRESENTATIONS IN CONNECTION WITH THIS OFFERING OTHER THAN THOSE CONTAINED IN
THIS PROSPECTUS AND, IF GIVEN OR MADE, SUCH OTHER INFORMATION AND
REPRESENTATIONS MUST NOT BE RELIED UPON AS HAVING BEEN AUTHORIZED BY US. NEITHER
THE DELIVERY OF THIS PROSPECTUS NOR ANY SALE OF SHARES OF OUR COMMON STOCK
COVERED BY THIS PROSPECTUS SHALL, UNDER ANY CIRCUMSTANCES, CREATE ANY
IMPLICATION THAT THERE HAS BEEN NO CHANGE IN OUR AFFAIRS SINCE THE DATE OF THIS
PROSPECTUS OR THAT THE INFORMATION CONTAINED HEREIN IS CORRECT AS OF ANY TIME
SUBSEQUENT TO ITS DATE. THIS PROSPECTUS DOES NOT CONSTITUTE AN OFFER TO SELL OR
A SOLICITATION OF AN OFFER TO BUY ANY SECURITIES OTHER THAN THE REGISTERED
SECURITIES TO WHICH IT RELATES. THIS PROSPECTUS DOES NOT CONSTITUTE AN OFFER TO
SELL OR A SOLICITATION OF AN OFFER TO BUY ANY SECURITIES IN ANY CIRCUMSTANCES IN
WHICH THE OFFER OR SOLICITATION IS UNLAWFUL.

                SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS

      This prospectus contains forward-looking statements that involve
substantial risks and uncertainties. You can identify these statements by
forward-looking words such as "anticipate," "believe," "could," "estimate,"
"expect," "intend," "may," "should," "will" and "would" or similar words. You
should read statements that contain these words carefully because they discuss
our future expectations, contain projections of our future results of operations
or of our financial position or state other "forward-looking" information. We
believe that it is important to communicate our future expectations to our
stockholders. However, there may be events in the future that we are not able to
accurately predict or control. The factors listed below in the section captioned
"Risk Factors," as well as any cautionary language in this prospectus, provide
examples of risks, uncertainties and events that may cause our actual results to
differ materially from the expectations we describe in our forward-looking
statements. Before you invest in our common stock, you should be aware that the
occurrence of the events described in these risk factors and elsewhere in this
prospectus could have a material adverse effect on our business, results of
operations, financial position and the price of our common stock.


                                       4


                                   THE COMPANY

      We are a leading and rapidly growing contract sales organization, CSO,
providing customized product detailing programs and other marketing and
promotional services to the United States pharmaceutical industry. We have
achieved our leadership position in the CSO industry based on 12 years of
designing and executing customized product detailing programs for many of the
pharmaceutical industry's largest companies, including Abbott, Allergan,
Astra-Zeneca, Aventis Pharma, Bayer, Glaxo Wellcome, Novartis, Pfizer, Procter &
Gamble, Hofmann LaRoche and Solvay/Unimed. We have designed programs that
promote more than 100 different products, including such leading prescription
medications as Imitrex(R), Flonase(R), Prilosec(R), Wellbutrin(R) and
Cardura(R), as well as a number of leading OTC products, to hospitals,
pharmacies and physicians in more than 25 different specialties.

      Product detailing involves meeting face-to-face with targeted prescribers
to provide a technical review of the product being promoted. CSOs have evolved
from providing detailing support for over-the-counter products into a
full-service industry handling some of the leading prescription pharmaceutical
compounds. Since the early 1990s, the United States pharmaceutical industry has
increasingly used CSOs to provide the detailing services to introduce new
products, reintroduce older products, supplement existing sales efforts, raise
promotional barriers to entry for competitors and demonstrate the incremental
sales impact of detailing a particular product.

Recent Developments

      In October 2000, our wholly owned subsidiary, LifeCycle Ventures, Inc.
(LCV), signed a five-year agreement with Glaxo Wellcome for the exclusive U.S.
marketing, sales and distribution rights for Ceftin(R) Tablets and Ceftin(R) for
Oral Suspension (cefuroxime axetil), two dosage forms of a cephalosporin
antibiotic. Ceftin, which is indicated for acute bacterial respiratory
infections such as acute sinusitis, bronchitis and otitis media , generated over
$332 million in U.S. sales in 1999. Ceftin is the top selling oral cephalosporin
in the U.S. and throughout the world. In July 2000, Ceftin was recommended by
the Sinus and Allergy Health Partnership as first-line treatment for acute
bacterial rhinosinusitis. In January 1999, the Centers for Disease Control and
Prevention (CDC) issued guidelines recommending Ceftin as one of only two oral
antibiotics as second-line treatment of acute bacterial otitis media. Glaxo
Wellcome retains certain regulatory responsibilities for Ceftin and ownership of
all intellectual property relevant to Ceftin and will continue to manufacture
the product.

      The LCV service offering provides pharmaceutical manufacturers with a new
approach toward managing the resource constraints inherent in a large product
portfolio. The mounting pressure to launch new drugs and quickly maximize sales
of products in the growth phase of their lifecycles often leaves other products
that could benefit from intensified sales and marketing efforts. LCV helps to
maximize the sales and profit potential of these products by funding and
managing their commercialization in return for a percentage of the sales.

      As part of our agreement with Glaxo Wellcome, LCV is required to purchase
certain minimum levels of Ceftin during each calendar quarter. In addition, LCV
purchased Glaxo Wellcome's inventory of Ceftin product that existed as of
October 1, 2000. In order to meet anticipated demand, LCV intends to maintain an
inventory of Ceftin that we expect to average between $30 to $60 million in
foreseeable periods. In the event that management's estimates of the demand for
Ceftin are not accurate, or the timing on collections of Ceftin related
receivables is slower than anticipated, the LCV - Ceftin transaction could have
a material adverse impact on the Company's results of operations, cash


                                       5


flows and liquidity. Our agreement with Glaxo Wellcome is cancelable by either
party upon not less than 120 days written notice.

Miscellaneous

      We were organized in February 1998 under the laws of the state of
Delaware. Our predecessor was incorporated under the laws of the state of New
Jersey in March 1988. Our principal executive office is located at 10
Mountainview Road, Upper Saddle River, New Jersey 07458, telephone number (201)
258-8450.

                                  RISK FACTORS

      You should carefully consider the following risks, which are not
necessarily listed in order of priority, before making an investment decision.
The risks described below are not the only ones that we face. Our business,
operating results or financial condition could be materially adversely affected
by any of these risks. The trading price of our common stock could decline due
to any of these risks and you may lose all or part of your investment. You
should also refer to the other information included in this prospectus.

             Risks Related to Our New Life Cycles Ventures Business

      We have entered into a new business with which we have no prior experience
and, therefore, our prospects for success are uncertain.

      In October 2000 we entered into an agreement with Glaxo Wellcome, the
owner of all the rights to and the manufacturer of the antibiotic Ceftin. Under
this agreement, we acquired the exclusive right to distribute Ceftin in the
United States. This is an entirely new business for us and, as such, we face all
the risks generally associated with the marketing and distribution of
pharmaceutical products. These risks include the following:

      o     competition from new or existing drug products, including
            introduction of generic equivalents prior to the expiration of
            Ceftin's patents;

      o     obtaining capital to finance the expansion of the business;

      o     identifying and obtaining the rights to sell and distribute
            pharmaceutical products;

      o     attracting, hiring and retaining qualified personnel;

      o     establishing and maintaining relationships with drug wholesalers,
            third party payors and other distributors;

      o     establishing inventory control procedures; and

      o     complying with regulatory requirements.


                                       6


      As a result of our agreement with Glaxo Wellcome, we anticipate that our
operating expenditures will increase significantly. These expenditures include
payments to third parties for inventory maintenance and control, distribution
services and accounts receivable administration, as well as expenditures for
sales and marketing.

      If we are unable to increase sales of Ceftin, or if sales of Ceftin
decline, our revenues from Ceftin will be limited, which could result in a
decline in our stock price.

      Decreased or lower-than-anticipated demand for Ceftin, or our inability to
meet demand, could materially adversely affect our operating results and harm
our business. Other factors that could adversely affect sales of Ceftin include:

      o     competition from existing products or development of new products;

      o     our ability to maintain adequate and uninterrupted sources of supply
            to meet demand;

      o     contamination of product lots or product recalls; and

      o     changes in private health insurer reimbursement rates or policies
            for Ceftin.

      The market demand for cephalosporin antibiotics, such as Ceftin, in the
United States has been declining as a percentage of overall antibiotic sales.
While Ceftin sales have been stable, we cannot give any assurance that we will
be able to maintain or increase the market for Ceftin. Under our agreement with
Glaxo Wellcome, we are required to purchase minimum amounts of the drug
regardless of sales. If we cannot maintain or increase sales of Ceftin from
their current levels, our business, operations and financial results could be
adversely affected.

      We depend on Glaxo Wellcome to continue to manufacture sufficient
quantities of Ceftin to meet continued demand for the product.

      We depend on Glaxo Wellcome to continue to manufacture Ceftin and there
are no assurances that Glaxo Wellcome will continue to manufacture sufficient
quantities of Ceftin to meet the demand for the drug. If market demand for
Ceftin grows, limits on our current sources of supply for Ceftin could constrain
our sales growth.

      If we are unable to attract and retain key employees and consultants, our
business could be harmed.

      The success of LCV in general and in regard to Ceftin in particular,
depends, in large part, on our ability to attract and retain highly qualified
and experienced management, administrative and marketing personnel. Competition
for personnel among companies in the pharmaceutical industry is intense. We
cannot assure you that we will be able to attract or retain the personnel
necessary to support the growth of our LCV business.


                                       7


      We depend on third parties, over whom we have no control, for client
maintenance, contract administration, inventory control, distribution, and
accounts receivable administration.

      We do not have the personnel or expertise necessary to fully execute the
Ceftin agreement. Until March 2001 Glaxo Wellcome has agreed to continue to
administer contractual relationships with Ceftin customers. We have no existing
relationships with drug wholesalers, government agencies or third party payors,
which is critical for our success. If we cannot establish these relationships
before April 2001, we may not be able to maintain and/or expand our contractual
relationship with these distribution sources. This could have an adverse effect
on our financial results. In addition, we have also entered into an agreement
with an unrelated third party to provide us with inventory control, distribution
and accounts receivable administration services. We have no experience dealing
with this third party vendor and we cannot assure you that they can provide us
with these services efficiently and reliably. We need to continually monitor
their performance. If we are forced to terminate our relationship with this
third party, we will need to find a suitable replacement quickly. We cannot
assure you that we will be able to find a suitable replacement quickly so that
our performance under the Glaxo Wellcome agreement will not be adversely
affected in a material manner.

      Failure to have Ceftin designated for reimbursement by third party payors
will adversely affect our sales.

      The use of Ceftin depends substantially on governmental agencies, private
health insurers and health maintenance organizations (HMO's) including Ceftin on
their formulary lists. There are many considerations that determine whether a
particular product will be approved by these agencies and organizations,
including price. If Ceftin is not included on formulary list of these agencies
and organizations, and therefore not approved for use by affiliated physicians,
demand for Ceftin could decline which would adversely impact our results of
operations. In addition, any change in reimbursement rates or reimbursement
policies by these organizations could adversely affect the market for Ceftin.

      If Ceftin's patent expires, the introduction of generic alternatives will
adversely impact the market for Ceftin.

      Ceftin Tablets and Ceftin for Oral Suspension are covered by patents which
expire in July 2003 and May 2008, respectively. Glaxo Wellcome retains all of
the patent rights to Ceftin. However, it is under no obligation to defend those
rights or seek to extend the patent rights. If the patent rights to Ceftin are
allowed to expire or if Glaxo Wellcome elects not to defend those rights,
generic alternatives are likely to be introduced and sales of Ceftin will
suffer. This will have a material adverse affect on our business, results of
operations and financial condition.

      We may be required to defend lawsuits or pay damages for product liability
claims.

      Product liability is a major risk in distributing and marketing
pharmaceutical products. We could face substantial product liability exposure
for products that we sell. Product liability claims, regardless of their merits,
could be costly and divert management's attention, or adversely affect our
reputation and the demand for our products. Although we currently maintain
product liability insurance coverage there is no assurance that we will continue
to maintain such coverage or that any such coverage will be adequate to offset
potential damages.


                                       8


                               Other Risk Factors

      If the pharmaceutical industry does not continue to use, or fails to
increase its use of, third party service organizations to market and promote its
products, our business would be seriously harmed.

      We have generated substantially all of our revenue from providing product
detailing and promotional and marketing services to pharmaceutical companies. We
have benefited from the growing trend of pharmaceutical companies to outsource
marketing and promotional programs. We cannot be certain that this trend will
continue. For example, the growth in outsourcing is driven, in part, by the
growth in the number of pharmaceutical products developed over the last few
years. However, recently there has been a decrease in the number of new ethical
compounds coming to market. If this trend continues, pharmaceutical companies
may reduce their outsourcing programs. Furthermore, the trend in the
pharmaceutical industry toward consolidation, by merger or otherwise, may result
in a reduction in the use of CSOs. A significant change in the direction of the
outsourcing trend generally, or a trend in the pharmaceutical industry not to
use, or to reduce the use of, outsourced marketing services, such as those we
provide, would have a material adverse effect on our business.

      A decrease in marketing or promotional expenditures by the pharmaceutical
industry as a result of private initiatives, government reform or otherwise,
could have an adverse affect on our business.

      Our business, financial condition and results of operations depend on
marketing and promotional expenditures by pharmaceutical companies for their
products. Because we generate substantially all of our revenue from product
detailing and promotional and marketing programs, unfavorable developments in
the pharmaceutical industry could adversely affect our business. These
developments could include reductions in expenditures for marketing and
promotional activities or a shift in marketing focus away from product
detailing. Promotional, marketing and sales expenditures by pharmaceutical
companies could also be negatively impacted by government reform or private
market initiatives intended to reduce the cost of pharmaceutical products or by
government, medical association or pharmaceutical industry initiatives designed
to regulate the manner in which pharmaceutical companies promote their products.

      Most of our revenue is derived from a limited number of clients, the loss
of any one of which could adversely affect our business.

      Our revenue and profitability are highly dependent on our relationships
with a limited number of large pharmaceutical companies. In 1999, our four
largest clients accounted for approximately 30%, 22%, 19% and 6%, respectively,
or a total of 77% of our revenue. We are likely to continue to experience a high
degree of client concentration, particularly if there is further consolidation
within the pharmaceutical industry. The loss or a significant reduction of
business from any of our major clients could have a material adverse effect on
our business and results of operations.

      Our contracts are short-term agreements and are subject to cancellation at
any time, which may result in lost revenue and additional costs and expenses.

      Our contracts are generally for a term of one year and may be terminated
by the client at any time for any reason. The termination of a contract by one
of our major clients would not only result in lost revenue, but may cause us to
incur additional costs and expenses. For example, all of our sales


                                       9


representatives are employees rather than independent contractors. Accordingly,
upon termination of a contract, unless we can immediately transfer the related
sales force to a new program, we either must continue to compensate those
employees, without realizing any related revenue, or terminate their employment.
If we terminate their employment, we may incur significant expenses relating to
their termination.

      We may lose money on fixed-fee contracts and performance-based contracts.

      Substantially all of our contracts are fixed fee arrangements. We also
enter into some contracts in which a portion of our fees are contingent on
meeting performance objectives. Finally, we are exploring the possibility of
entering into contracts under which we may share the costs of a detailing
program with the client in exchange for a contingent fee based on the future
sales of the product being promoted or some other performance based criteria.
Accordingly, if we underestimate the costs associated with the services to be
provided under a particular contract, or if there are unanticipated increases in
our operating or administrative expenses, or if we fail to meet certain
performance objectives, or if we incorrectly assess the market potential of a
particular product, the margins on that contract and our overall profitability
may be adversely affected.

      We have recently experienced rapid growth in the number of employees, the
size of our programs and the scope of our operations. Our ability to manage such
growth effectively will depend upon our ability to enhance our management team
and our ability to attract and retain skilled employees. Our success will also
depend on the ability of our officers and key employees to continue to implement
and improve our operational, management information and financial control
systems, and to expand, train and manage our workforce. Failure to manage growth
effectively could have a material adverse effect on our business and results of
operations.

      Our business has expanded rapidly. If we cannot manage our growth
effectively, we will not be able to fulfill our obligations to our clients
effectively and our business will suffer.

      We have recently experienced rapid growth in the number of employees, the
size of our programs and the scope of our operations. Our ability to manage our
growth effectively will depend upon our ability to enhance our management team
and our ability to attract and retain skilled employees. Our success will also
depend on the ability of our officers and key employees to continue to implement
and improve our operational, management information and financial control
systems, and to expand, train and manage our workforce. Failure to manage growth
effectively could have a material adverse effect on our business and results of
operations.

      The CSO industry is highly competitive and our failure to address
competitive developments promptly will limit our ability to retain and increase
our market share.

      Traditionally, our primary competitors were the in-house sales and
marketing departments of pharmaceutical companies and other CSOs, such as
Innovex, a subsidiary of Quintiles Transnational, the various sales and
marketing affiliates of Ventiv Health (formerly, Snyder Communications) and
Nelson Professional Sales, a division of Nelson Communications, Inc. However,
there are relatively few barriers to entry in the CSO industry and, as the CSO
industry continues to evolve, new competitors are likely to emerge. For example,
recently, two major wholesale drug distributors have begun to provide product
detailing services. Many of our current and potential competitors are larger
than we are and have substantially greater capital, personnel and other
resources than we have.


                                       10


Increased competition may lead to price and other forms of competition that
could have a material adverse effect on our market share, business and results
of operations.

      As a result of competitive pressures, various organizations providing
services to the pharmaceutical industry are consolidating and are becoming
targets of global organizations. This trend is likely to produce increased
competition for clients. In addition, if the trend in the pharmaceutical
industry towards consolidation continues, pharmaceutical companies may have
excess in-house sales force capacity and they may, as a result, reduce or
eliminate their use of CSOs or choose to award their product detailing and other
marketing and promotional programs to organizations that can provide a broader
range of services. Although we intend to monitor industry trends and respond
appropriately, we may not be able to anticipate and successfully respond to such
trends.

      Our business will suffer if we fail to attract and retain experienced
sales representatives.

      The success and growth of our business depends on our ability to attract
and retain qualified and experienced pharmaceutical sales representatives. There
is intense competition for experienced pharmaceutical sales representatives from
competing CSOs and pharmaceutical companies. On occasion our clients have hired
the sales representatives that we trained to detail its products. We cannot be
certain that we can continue to attract and retain qualified personnel. If we
cannot attract, retain and motivate qualified sales personnel, we will not be
able to expand our business and our ability to perform under our existing
contracts will be impaired.

      Our business will suffer if we lose certain key management personnel.

      The success of our business also depends on our ability to attract, retain
and motivate qualified senior management, financial and administrative personnel
who are in high demand and who often have multiple employment options.
Currently, we depend on a number of our senior executives, including Charles T.
Saldarini, our vice chairman and chief executive officer; Steven K. Budd, our
president and chief operating officer; and Bernard C. Boyle, our chief financial
officer. The loss of the services of any one or more of these executives could
have a material adverse effect on our business, financial condition and results
of operations. Except for a $5 million key-man life insurance policy on the life
of Mr. Saldarini and a $3 million policy on the life of Mr. Budd, we do not
maintain and do not contemplate obtaining insurance policies on any of our
employees.

      Government or private initiatives to reduce healthcare costs could have a
material adverse effect on the pharmaceutical industry and on us.

      The primary trend in the United States healthcare industry is toward cost
containment. Comprehensive government healthcare reform intended to reduce
healthcare costs, the growth of total healthcare expenditures and expanded
healthcare coverage for the uninsured have been proposed in the past and may be
considered again in the near future. Implementation of government healthcare
reform may adversely affect promotional and marketing expenditures by
pharmaceutical companies, which could decrease the business opportunities
available to us. In addition, the increasing use of managed care, centralized
purchasing decisions, consolidations among and integration of healthcare
providers are continuing to affect purchasing and usage patterns in the
healthcare system. Decisions regarding the use of pharmaceutical products are
increasingly being consolidated into group purchasing organizations, regional
integrated delivery systems and similar organizations and are becoming more
economically focused, with decision makers taking into account the cost of the
product and whether a product reduces


                                       11


the cost of treatment. Significant cost containment initiatives adopted by
government or private entities could have a material adverse effect on our
business.

      Our failure, or that of our clients, to comply with applicable healthcare
regulations could limit, prohibit or otherwise adversely impact our business
activities.

      Various laws, regulations and guidelines promulgated by government,
industry and professional bodies affect, among other matters, the provision,
licensing, labeling, marketing, promotion, sale and distribution of healthcare
services and products, including pharmaceutical products. In particular, the
healthcare industry is subject to various Federal and state laws pertaining to
healthcare fraud and abuse, including prohibitions on the payment or acceptance
of kickbacks or other remuneration in return for the purchase or lease of
products that are paid for by Medicare or Medicaid. Sanctions for violating
these laws include civil and criminal fines and penalties and possible exclusion
from Medicare, Medicaid and other Federal healthcare programs. Although we
believe our current business arrangements do not violate these Federal and state
fraud and abuse laws, we cannot be certain that our business practices will not
be challenged under these laws in the future or that a challenge would not have
a material adverse effect on our business, financial condition and results of
operations. Our failure, or the failure of our clients, to comply with these
laws, regulations and guidelines, or any change in these laws, regulations and
guidelines may, among other things, limit or prohibit our business activities or
those of our clients, subject us or our clients to adverse publicity, increase
the cost of regulatory compliance or subject us or our clients to monetary fines
or other penalties.

      The costs and difficulties of acquiring and integrating new businesses
could impede our future growth and adversely affect our competitiveness.

      As part of our growth strategy, we constantly evaluate new acquisition
opportunities. Acquisitions involve numerous risks and uncertainties, including:

      o     the difficulty of identifying appropriate acquisition candidates;

      o     the difficulty integrating the operations and products and services
            of the acquired companies;

      o     the expenses incurred in connection with the acquisition and
            subsequent integration of operations and products and services;

      o     the impairment of relationships with employees, customers or vendors
            as a result of changes in management and ownership;

      o     the diversion of management's attention from other business
            concerns; and

      o     the potential loss of key employees or customers of the acquired
            company.

      Acquisitions of companies outside the United States also may involve the
            following additional risks:

      o     assimilating differences in international business practices;


                                       12


      o     overcoming language differences;

      o     exposure to currency fluctuations;

      o     difficulties in complying with a variety of foreign laws;

      o     unexpected changes in regulatory requirements;

      o     difficulties in staffing and managing foreign operations; and

      o     potentially adverse tax consequences.

      We may be unable to successfully identify, complete or integrate any
future acquisitions, and acquisitions that we complete may not contribute
favorably to our operations and future financial condition. We may also face
increased competition for acquisition opportunities, which may inhibit our
ability to consummate suitable acquisitions on favorable terms.

      Our major stockholder will continue to have effective control of us after
this offering and could delay or prevent a change in corporate control that
stockholders may believe will improve management.

      John P. Dugan, our chairman, beneficially owns approximately 37% of our
outstanding common stock (excluding shares issuable upon the exercise of
options). As a result, Mr. Dugan will be able to exercise substantial control
over the election of all of our directors, and to determine the outcome of most
corporate actions requiring stockholder approval, including a merger with or
into another company, the sale of all or substantially all of our assets and
amendments to our certificate of incorporation.

      We have anti-takeover defenses that could delay or prevent an acquisition
and could adversely affect the price of our common stock.

      Our certificate of incorporation and bylaws include certain provisions,
such as three classes of directors, which are intended to enhance the likelihood
of continuity and stability in the composition of our board of directors. These
provisions may render the removal of our directors and management more difficult
and adversely affect the price of our common stock. In addition, our certificate
of incorporation authorizes the issuance of "blank check" preferred stock. This
provision could have the effect of delaying, deterring or preventing a future
takeover or a change in control, unless the takeover or change in control is
approved by our board of directors, even though the transaction might offer our
stockholders an opportunity to sell their shares at a price above the current
market price.

      Our quarterly revenues and operating results may vary which may cause the
price of our common stock to fluctuate.

      Our quarterly operating results may vary as a result of a number of
factors, including:

      o     the commencement, delay, cancellation or completion of programs;

      o     the mix of services provided;


                                       13


      o     the timing and amount of expenses for implementing new programs and
            services;

      o     the accuracy of estimates of resources required for ongoing
            programs;

      o     uncertainty related to compensation based on achieving performance
            benchmarks;

      o     the timing and integration of acquisitions;

      o     changes in regulations related to pharmaceutical companies; and

      o     general economic conditions.

      In addition, generally, we recognize revenue as services are performed,
while program costs, other than training costs, are expensed as incurred. As a
result, during the first two to three months of a new contract, we may incur
substantial expenses associated with staffing that new program without
recognizing any revenue under that contract. This could have an adverse impact
on our operating results and the price of our common stock for the quarters in
which these expenses are incurred.

      We believe that quarterly comparisons of our financial results are not
necessarily meaningful and should not be relied upon as an indication of future
performance. Fluctuations in quarterly results could adversely affect the market
price of our common stock in a manner unrelated to our long term operating
performance.


                                       14


                                 USE OF PROCEEDS

      All shares of our common stock offered by this prospectus are being
registered for the account of the selling stockholders. We will not receive any
of the proceeds from the sale of these shares.

                              SELLING STOCKHOLDERS

      The selling stockholders acquired the shares of common stock that they are
selling from us in connection with our acquisition of TVG, Inc. in May 1999.

      The following table sets forth the name and the number of shares of our
common stock beneficially owned by each selling stockholder (either directly or
through entities which it controls) as of October 31, 2000 and as adjusted to
reflect the sale of the shares offered by this prospectus, by each selling
stockholder.

      Except as otherwise indicated, the persons listed below have sole voting
and investment power with respect to all shares of common stock owned by them.
All information with respect to beneficial ownership has been furnished to us by
the respective stockholder.



                                  Shares Beneficially                        Shares Beneficially
                                    Owned Prior to                             Owned After the
                                      Offering(1)                                 Offering
                               --------------------------                   ----------------------
                                                            Shares Being
 Name of Beneficial Owner         Number        Percent       Offered        Number       Percent
- ----------------------------   -------------    ---------   -------------   ---------     --------
                                                                             
Frank Smith..............        148,085          1.1%        148,085         -0-           0%
Marc Julius..............        148,084          1.1%        148,084         -0-           0%
Gail Keppler.............        148,085          1.1%        148,085         -0-           0%
Gary Silverman...........        148,085          1.1%        148,085         -0-           0%
John McNichol............        148,084          1.1%        148,084         -0-           0%
Robin Putzrath...........        148,085          1.1%        148,085         -0-           0%
Mary Attig...............         74,049           *           74,049         -0-           0%
Bill Wrubel..............         74,048           *           74,048         -0-           0%
Eric Rodes...............         50,160           *           50,160         -0-           0%
H. Dennis Zanella........         44,429           *           44,429         -0-           0%


- ----------
* Less than 1%.

(1)   Beneficial ownership is determined in accordance with the rules of the
      Securities and Exchange Commission. In computing the number of shares
      beneficially owned by a person and the percentage ownership of that
      person, shares of common stock underlying options and warrants held by
      that person that are currently exercisable or exercisable within 60 days
      of October 31, 2000 are deemed outstanding. These shares, however, are not
      deemed outstanding for the purpose of computing the percentage ownership
      of any other person.


                                       15


                              PLAN OF DISTRIBUTION

      The selling stockholders have advised us that the shares of common stock
covered by this prospectus may be offered and sold by them or by their pledgees,
donees, transferees or other successors in interest, in private or public
transactions, in transactions involving principals, in transactions involving
brokers, or by any other lawful methods. Sales through brokers may be made by
any method of trading authorized by any stock exchange or market on which shares
of our common stock may be listed, including block trading in negotiated
transactions. These brokers may act as dealers by purchasing any or all of the
shares of common stock covered by this prospectus, either as agents for others
or as principals for their own accounts, and reselling those shares under this
prospectus. Sales of the shares covered by this prospectus are, in general,
expected to be made at the market price prevailing at the time of each sale.
However, prices in negotiated transactions may differ considerably.

      The selling stockholders may also offer to sell and sell the shares
covered by this prospectus in options transactions. In addition, the selling
stockholders may pledge their shares to their brokers under the margin
provisions of customer agreements. If a selling stockholder defaults on a margin
loan, the broker may, from time to time, offer and sell the pledged shares.

      Broker-dealers engaged by the selling stockholders may arrange for other
brokers-dealers to participate in sales. Broker-dealers may receive commissions
or discounts from the selling stockholders (or, if any broker-dealer acts as
agent for the purchaser of shares, from the purchaser) in amounts to be
negotiated. Each of the selling stockholders has advised us that he or she does
not anticipate paying any consideration other than usual and customary broker's
commissions in connection with sales of the shares covered by this prospectus.

      Each of the selling stockholders is acting independently of us in making
decisions with respect to the timing, manner and size of each sale. In addition,
any shares covered by this prospectus that qualify for sale under Rule 144 under
the Securities Act may be sold under Rule 144 rather than under this prospectus.

      In offering the shares covered by this prospectus, each of the selling
stockholders and any broker-dealers who execute sales for the selling
stockholders may be considered to be "underwriters" within the meaning of the
Securities Act, and any profits realized by the selling stockholder and the
compensation of the broker-dealer may be deemed underwriting discounts and
commissions.

      We have agreed to indemnify in certain circumstances each of the selling
stockholders and any underwriter and certain control and other persons related
to these persons against certain liabilities, including liabilities under the
Securities Act. Each of the selling stockholders has agreed to indemnify us in
certain circumstances and certain related persons against certain liabilities,
including liabilities under the Securities Act.

      We have agreed with each of the selling stockholders to keep the
registration statement of which this prospectus constitutes a part effective
until the earlier of (i) the date all of the shares covered by this prospectus
have been sold by the selling stockholders or (ii) the first anniversary date of
this prospectus. We intend to deregister any of the shares not sold by the
selling stockholders at the end of that period.


                                       16


      We will pay all of the expenses relating to the registration of the shares
covered by this prospectus except for selling commissions. These expenses are
estimated at $80,000.

                                  LEGAL MATTERS

      Various legal matters in connection with this offering will be passed upon
for us by Morse, Zelnick, Rose & Lander, LLP, New York, New York.

                                     EXPERTS

      The audited consolidated financial statements incorporated in this
prospectus by reference to the Annual Report on Form 10-K of Professional
Detailing, Inc. for the year ended December 31, 1999, except as they relate to
TVG, Inc. for 1997 and 1998, have been audited by PricewaterhouseCoopers LLP,
independent accountants, and, insofar as they relate to TVG, Inc. for 1997 and
1998, by Grant Thornton LLP, independent accountants. These financial statements
have been incorporated in reliance on the reports of such independent
accountants given on the authority of those firms as experts in auditing and
accounting.


                                       17